Roila, F.Molassiotis, A.Herrstedt, J.Aapro, M.Gralla, R.Bruera, E.Clark-Snow, R.Dupuis, L.Einhorn, L.Feyer, P.Hesketh, P.Jordan, K.Olver, I.Rapoport, B.Roscoe, J.Ruhlmann, C.Walsh, D.Warr, D.van der Wetering, M.on, B.O.T.P.O.T.M.C.C.C.2017-08-032017-08-032016Annals of Oncology, 2016; 27(suppl. 5):v119-v1330923-75341569-8041http://hdl.handle.net/2440/106572Despite the considerable progress achieved in the last 30 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In the late 1990s, several professional organisations published recommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and/or radiotherapy. The European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) published the results of the third Consensus Conference on antiemetics held in Perugia in June 2009 in Annals of Oncology in 2010 [1]. An update of these recommendations, including studies published from 1 January 2009 to 30 June 2015, was discussed in Copenhagen in June 2015 and is presented in this paper. The methodology for the guideline process is described in detail in the 2010 publication [1]. To change a 2010 recommendation or for a new guideline recommendation to be accepted, a consensus of at least 67% of the expert panellists was needed. As a general rule, the panel considered changes of 10% or greater to be sufficient to warrant the changing of a recommendation.enCopyright © 2017 European Society for Medical Oncologyparticipants of the MASCC/ESMO Consensus Conference Copenhagen 2015Journal article003006138310.1093/annonc/mdw2700003851252000112-s2.0-84995772540278319Olver, I. [0000-0001-5478-1576]